|ATC code||N06CA02 (WHO)|
Flupentixol/melitracen (trade name Deanxit, Placida, Franxit, Anxidreg) is a combination of two psychoactive agents which has antidepressant properties. It is designed for short term usage only. It is produced by Lundbeck.
Flupentixol/melitracen were banned in India by the country's Ministry of Health and Family Welfare on July 11, 2014, and Lundbeck plans to take legal action to have the ban lifted.
Other Brand names
Brand names include:
- Frenxit (Beximco Pharmaceuticals Ltd.)
- Sensit (Eskayef Bangladesh Ltd.)
- Renxit (Renata Ltd.)
- Melixol (Square Pharmaceuticals Ltd.)
- Melanxit (Organic Health Care Ltd.)
- Benzit (Bio-Pharma Ltd.)
- Leanxit (ACME Laboratories Ltd.)
- Sweetman, Sean C., ed. (2009). "Preparations". Martindale: The complete drug reference (36th ed.). London: Pharmaceutical Press. p. 2607. ISBN 978-0-85369-840-1.
- "Ministry of Health and Family Welfare (Department of Health and Family Welfare) Notification, New Delhi" (PDF). The Gazette of India. July 11, 2014. Retrieved March 19, 2015 – via drugscontrol.org.
- Soma Das, ET Bureau (July 25, 2014). "Lundbeck to seek legal recourse after health ministry bans Deanxit again". Economic Times. Retrieved March 19, 2015.